

Azmil H Abdul-Rahim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3026543/publications.pdf>

Version: 2024-02-01

142
papers

42,497
citations

36203

51
h-index

9553

142
g-index

142
all docs

142
docs citations

142
times ranked

35691
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
2	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, e147-e239.	1.2	7,017
3	Angiotensinâ€“Neprilysin Inhibition versus Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 993-1004.	13.9	5,052
4	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. <i>New England Journal of Medicine</i> , 2011, 364, 11-21.	13.9	2,491
5	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
6	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. <i>New England Journal of Medicine</i> , 2003, 349, 1893-1906.	13.9	2,240
7	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , 2003, 362, 759-766.	6.3	1,752
8	Reninâ€“Angiotensinâ€“Aldosterone System Inhibitors in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 1653-1659.	13.9	1,732
9	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet, The</i> , 2003, 362, 772-776.	6.3	1,623
10	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1387-1395.	6.3	990
11	Obesity Is a Risk Factor for Severe COVID-19 Infection. <i>Circulation</i> , 2020, 142, 4-6.	1.6	595
12	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
13	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 1377-1385.	1.0	549
14	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 1482-1487.	1.6	528
15	Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003. <i>Circulation</i> , 2009, 119, 515-523.	1.6	468
16	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	2.9	434
17	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018, 137, 961-972.	1.6	368
18	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009, 11, 170-177.	2.9	326

#	ARTICLE	IF	CITATIONS
19	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018, 20, 1230-1239.	2.9	295
20	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021, 143, 516-525.	1.6	237
21	Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2175-2182.	1.0	213
22	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 122, 597-602.	1.6	195
23	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008, 29, 1224-1240.	1.0	184
24	Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008, 10, 149-156.	2.9	183
25	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145
26	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. <i>Circulation</i> , 2016, 133, 2254-2262.	1.6	142
27	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 271-277.	1.2	141
28	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011, 32, 1227-1234.	1.0	130
29	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 337-341.	2.9	129
30	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 590-595.	1.6	123
31	Lung Ultrasound in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 849-858.	1.9	116
32	Clinical Selection Strategies to Identify Ischemic Stroke Patients With Large Anterior Vessel Occlusion. <i>Stroke</i> , 2017, 48, 290-297.	1.0	115
33	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	1.0	114
34	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	93
35	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 1486-1494.	1.6	92
36	Depression and anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional data from a regional stroke registry. <i>BMC Neurology</i> , 2014, 14, 198.	0.8	91

#	ARTICLE	IF	CITATIONS
37	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 844-851.	2.9	91
38	Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms. <i>Circulation</i> , 2012, 126, 2317-2323.	1.6	90
39	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	89
40	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin K Oral Anticoagulants (RAF-NOACs) Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	89
41	Ultrasound imaging of congestion in heart failure: examinations beyond the heart. <i>European Journal of Heart Failure</i> , 2021, 23, 703-712.	2.9	87
42	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85
43	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. <i>European Journal of Heart Failure</i> , 2010, 12, 17-24.	2.9	84
44	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Therapy). <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	83
45	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1199-1208.	2.2	83
46	BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 1149-1151.	1.8	83
47	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014, 7, 953-959.	1.6	80
48	Urate, Blood Pressure, and Cardiovascular Disease. <i>Hypertension</i> , 2021, 77, 383-392.	1.3	75
49	“Hearts and minds”: association, causation and implication of cognitive impairment in heart failure. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 22.	3.0	73
50	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 607-616.	2.9	71
51	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2019, 50, 2168-2174.	1.0	59
52	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. <i>Circulation: Heart Failure</i> , 2018, 11, e004745.	1.6	55
53	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. <i>Journal of the American Heart Association</i> , 2018, 7, e010133.	1.6	55
54	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53

#	ARTICLE	IF	CITATIONS
55	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the PRESERVE study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	2.9	52
56	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	52
57	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 504-510.	2.9	52
58	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019, 42, 1792-1799.	4.3	52
59	Return to the Workforce After First Hospitalization for Heart Failure. <i>Circulation</i> , 2016, 134, 999-1009.	1.6	50
60	How Small Is Too Small? A Systematic Review of Center Volume and Outcome After Cardiac Transplantation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 783-790.	0.9	48
61	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. <i>European Journal of Heart Failure</i> , 2015, 17, 1182-1191.	2.9	48
62	Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial infarction trial (VALIANT). <i>European Heart Journal</i> , 2009, 30, 1450-1456.	1.0	47
63	Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013306.	1.5	47
64	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021, 44, 1894-1897.	4.3	47
65	Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1139-1145.	2.9	45
66	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. <i>European Journal of Heart Failure</i> , 2018, 20, 268-277.	2.9	42
67	Effect of Nephylisin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021, 144, 199-209.	1.6	40
68	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 506-522.	1.1	39
69	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	2.9	37
70	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017, 38, ehw509.	1.0	36
71	The Incidence and Associated Factors of Early Neurological Deterioration After Thrombolysis. <i>Stroke</i> , 2020, 51, 2705-2714.	1.0	33
72	Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. <i>Journal of Neurology</i> , 2016, 263, 231-237.	1.8	32

#	ARTICLE	IF	CITATIONS
73	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema. <i>Stroke</i> , 2017, 48, 726-732.	1.0	32
74	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017, 188, 35-41.	1.2	32
75	Rationale for and design of the <sc>TRUE&A&H</sc> trial: the effects of ularitide on the short&term clinical course and long&term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	2.9	31
76	Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin&converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)&Added trial. <i>European Journal of Heart Failure</i> , 2008, 10, 157-163.	2.9	30
77	National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome. <i>Stroke</i> , 2015, 46, 395-400.	1.0	30
78	Anticoagulation After Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019, 50, 2093-2100.	1.0	29
79	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 727-735.	1.2	28
80	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. <i>Stroke</i> , 2022, 53, 2620-2627.	1.0	28
81	Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose Tolerance. <i>Circulation: Heart Failure</i> , 2013, 6, 203-210.	1.6	26
82	Statins and risk of poststroke hemorrhagic complications. <i>Neurology</i> , 2016, 86, 1590-1596.	1.5	26
83	Practical &1-2-3-4-Day&Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. <i>Stroke</i> , 2022, 53, 1540-1549.	1.0	26
84	Derivation and Validation of a Novel Prognostic Scale (Modified&Stroke Subtype, Oxfordshire) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 Mortality in Acute Stroke. <i>Stroke</i> , 2016, 47, 74-79.	1.0	25
85	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021, 44, 1877-1884.	4.3	25
86	Baseline characteristics of patients in the Reduction of Events with Darbeoetin alfa in Heart Failure trial (RED&HF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24
87	Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. <i>Heart</i> , 2014, 100, 557-562.	1.2	24
88	Biomarkers for Atrial Fibrillation Detection After Stroke. <i>Neurology</i> , 2021, 97, e1775-e1789.	1.5	23
89	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. <i>International Journal of Cardiology</i> , 2016, 209, 310-316.	0.8	22
90	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart&Failure (Part 2/5). <i>Journal of the American College of Cardiology</i> , 2019, 74, 683-698.	1.2	22

#	ARTICLE	IF	CITATIONS
91	Sex and Stroke in Thrombolized Patients and Controls. <i>Stroke</i> , 2017, 48, 367-374.	1.0	21
92	Barcelona Bioâ€HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. <i>European Journal of Heart Failure</i> , 2018, 20, 938-940.	2.9	20
93	Systolic blood pressure reduction during the first 24â€h in acute heart failure admission: friend or foe?. <i>European Journal of Heart Failure</i> , 2018, 20, 317-322.	2.9	20
94	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1022-1031.	2.9	20
95	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011, 13, 755-764.	2.9	19
96	National Institutes of Health Stroke Scale Item Profiles as Predictor of Patient Outcome. <i>Stroke</i> , 2015, 46, 2779-2785.	1.0	19
97	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <sc>ATMOSPHERE</sc> trial. <i>European Journal of Heart Failure</i> , 2018, 20, 136-147.	2.9	18
98	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. <i>Korean Circulation Journal</i> , 2019, 49, 469.	0.7	18
99	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (â€PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.	2.9	17
100	Heart Failure. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 117-135.	1.2	17
101	Body mass index and Bâ€lines on lung ultrasonography in chronic and acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1201-1209.	1.4	17
102	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. <i>European Journal of Heart Failure</i> , 2010, 12, 66-74.	2.9	16
103	Clinical characteristics and outcomes of patients with angina and heart failure in the <sc>CHARM</sc> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.0	16
104	A survey of opinion: When to start oral anticoagulants in patients with acute ischaemic stroke and atrial fibrillation?. <i>European Stroke Journal</i> , 2018, 3, 355-360.	2.7	16
105	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
106	The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1595-1604.	1.4	15
107	Characteristic Adverse Events and Their Incidence Among Patients Participating in Acute Ischemic Stroke Trials. <i>Stroke</i> , 2014, 45, 2677-2682.	1.0	14
108	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 57	1.0	14

#	ARTICLE	IF	CITATIONS
109	Cardiorenal risk reduction guidance in diabetes: can we reach consensus?. Lancet Diabetes and Endocrinology, 2020, 8, 357-360.	5.5	14
110	Improving economic evaluations in stroke: A report from the ESO Health Economics Working Group. European Stroke Journal, 2020, 5, 184-192.	2.7	13
111	Haemodynamic effects of the nitroxyl donor cimlanod (<sc>BMS</sc>â€986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 2021, 23, 1147-1155.	2.9	13
112	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy. JACC: Heart Failure, 2021, 9, 386-397.	1.9	11
113	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. Clinical Epidemiology, 2018, Volume 10, 917-930.	1.5	10
114	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 2021, 8, 129-138.	1.4	9
115	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <sc>HEAAL</sc> trial. European Journal of Heart Failure, 2021, 23, 1477-1484.	2.9	9
116	Paroxysmal atrial fibrillation after ischemic stroke: how should we hunt for it?. Expert Review of Cardiovascular Therapy, 2013, 11, 485-494.	0.6	8
117	Early in-hospital exposure to statins and outcome after intracerebral haemorrhage â€” Results from the Virtual International Stroke Trials Archive. European Stroke Journal, 2020, 5, 85-93.	2.7	8
118	The impact of atrial fibrillation type on the risks of thromboembolic recurrence, mortality and major haemorrhage in patients with previous stroke: A systematic review and meta-analysis of observational studies. European Stroke Journal, 2020, 5, 155-168.	2.7	8
119	Feasibility Platform for Stroke Studies. Stroke, 2015, 46, 137-142.	1.0	7
120	Prestroke CHA2DS2-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1363-1368.	0.7	7
121	Professional guideline versus product label selection for treatment with IV thrombolysis: An analysis from SITS registry. European Stroke Journal, 2018, 3, 39-46.	2.7	7
122	Lung ultrasound: monitoring congestion in patients with heart failure. European Journal of Heart Failure, 2019, 21, 1614-1615.	2.9	7
123	Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 2019, 21, 699-702.	2.9	7
124	Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation. Stroke, 2020, 51, 2347-2354.	1.0	7
125	Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 2021, 8, 1784-1795.	1.4	7
126	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Nonâ€“Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke, 2021, 52, 1450-1454.	1.0	7

#	ARTICLE	IF	CITATIONS
127	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. <i>European Stroke Journal</i> , 2020, 5, 374-383.	2.7	6
128	Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from <scp>PARAGONâ€HF</scp>. <i>European Journal of Heart Failure</i> , 2022, 24, 672-677.	2.9	6
129	Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)"â€ Circulation, 2021, 144, e40.	1.6	6
130	Screening for atrial fibrillation after stroke or TIA. <i>Lancet Neurology</i> , The, 2015, 14, 345-347.	4.9	5
131	Are you suffering from a large arterial occlusion? Please raise your arm!. <i>Stroke and Vascular Neurology</i> , 2018, 3, 215-221.	1.5	5
132	Paired vagus nerve stimulation for treatment of upper extremity impairment after stroke. <i>International Journal of Stroke</i> , 2022, 17, 1061-1066.	2.9	5
133	Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in) Tj ETQq1 1 0.784314 rgBT /Overlo	1.0	5
134	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. <i>European Stroke Journal</i> , 2019, 4, 55-64.	2.7	4
135	Effects of apixaban compared with warfarin as gain in event-free time " a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1311-1319.	0.8	4
136	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 295-301.	1.3	3
137	Zinc containing dental fixative causing copper deficiency myelopathy. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219802.	0.2	3
138	Stroke aetiological classification reliability and effect on trial sample size: systematic review, meta-analysis and statistical modelling. <i>Trials</i> , 2019, 20, 107.	0.7	3
139	Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials."â€ Circulation, 2015, 132, e358.	1.6	2
140	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.	2.7	1
141	Online Tool to Improve Stratification of Adverse Events in Stroke Clinical Trials. <i>Stroke</i> , 2016, 47, 882-885.	1.0	1
142	The role of single pill combination therapy in the prevention of ischaemic stroke. <i>Scottish Medical Journal</i> , 2019, 64, 126-132.	0.7	1